Measurement of utility values in the UK for health states related to immune thrombocytopenic purpura

Current Medical Research and Opinion

Volumn 26, Issue 8, 2010, Pages 1893-1903

  Szende, Agota ^a   Brazier, John ^b   Schaefer, Caroline ^c   Deuson, Robert ^d   Isitt, John J ^d   Vyas, Paresh ^e  

^a Springfield House ^*  (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c Outcome Services   (United States)

^d AMGEN INC   (United States)

^e UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Health states; Immune (idiopathic) thrombocytopenic purpura; Quality of life; Utility values

Indexed keywords

ROMIPLOSTIM;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; CLINICAL TRIAL; CORTICOSTEROID THERAPY; FEMALE; HEALTH STATUS; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; MAJOR CLINICAL STUDY; MALE; QUALITY OF LIFE; THROMBOCYTE COUNT; UNITED KINGDOM; WILCOXON SIGNED RANKS TEST;

ADULT; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; DATABASES, FACTUAL; FEMALE; GREAT BRITAIN; HEALTH STATUS; HEALTH SURVEYS; HUMANS; INTERNET; MALE; MIDDLE AGED; PUBLIC OPINION; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; QUALITY OF LIFE; QUESTIONNAIRES; RECEPTORS, FC; RECOMBINANT FUSION PROTEINS; REGRESSION ANALYSIS; THROMBOPOIETIN;

EID: 77954721452     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2010.494126     Document Type: Article

References (23)

1. George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996 Jul 1;88:3-40
2. McMillan R, Wang L, Tomer A, et al. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood 2004;103:1364-9
3. Macarthur D. Orphan drugs in Europe: pricing, reimbursement, funding and market access issues. Justpharmareports. 2008 [cited 2008; Available from: www.justpharmareports.com
4. Aledort LM, Lyons RM, Okano G, et al. The clinical and direct medical cost burden of splenectomy among managed care patients with chronic immune thrombocytopenic purpura (ITP). Abstract at the American Society of Hematology (ASH) Annual Meeting, 2006
5. McMillan R, Bussel JB, George JN, et al. Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura. Am J Hematol 2008;83:150-4
6. Snyder CF, Mathias SD, Cella D, et al. Health-related quality of life of immune thrombocytopenic purpura patients: results from a web-based survey. Curr Med Res Opin 2008;24:2767-76
7. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010;115:168-86
8. Bussel JB, Kuter DJ, George JN, et al. AMG 531, a thrombopoiesis- stimulat-ing protein, for chronic ITP. N Engl J Med 2006;355:1672-81
9. EuroQol-a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 1990;16:199-208
10. Amgen. A randomized, placebo controlled study evaluating the efficacy and safety of AMG 531 treatment of thrombocytopenic subjects with immune (idiopathic) thrombocytopenic purpura (ITP) prior to splenectomy (Protocol 20030212 Study Report): Data on file, Amgen; 2006 [NCT00102323]
11. Amgen. A randomized, placebo controlled study evaluating the efficacy and safety of AMG 531 treatment of thrombocytopenic subjects with immune (idiopathic) thrombocytopenic purpura (ITP) refractory to splenectomy (Protocol 20030105 Study Report): Data on file, Amgen; 2006 [NCT00102336]
12. Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 2008;371:395-403
13. Mathias SD, Bussel JB, George JN, et al. A disease-specific measure of health-related quality of life in adults with chronic immune thrombocytopenic purpura: psychometric testing in an open-label clinical trial. Clin Ther 2007; 29:950-62
14. Mathias SD, Gao SK, Rutstein M, et al. Evaluating clinically meaningful change on the ITP-PAQ: preliminary estimates of minimal important differences. Curr Med Res Opin 2009;25:375-83
15. Mathias SD, Bussel JB, George JN, et al. A disease-specific measure of health-related quality of life for use in adults with immune thrombocytopenic purpura: its development and validation. Health Qual Life Outcomes 2007;5:11
16. Furlong W, Feeny D, Torrance GW, et al. Guide to design and development of health-state utility instrumentation. Hamilton, Ontario: McMaster University, 1990
17. Torrance GW. Utility approach to measuring health-related quality of life. J Chronic Dis 1987;40:593-603
18. MVH Group. The measurement and valuation of health. Final report on the modelling of valuation tariffs York, UK: York Centre for Health Economics, 1995
19. Tufts Medical Center. The Center for the Evaluation of Value and Risk in Health. Cost-Effectiveness Analysis (CEA) Registry. [cited; Available from: https://research.tufts-nemc.org/cear/Default.aspx (Last updated through September 2009)
20. Xie F, Blackhouse G, Assasi N, et al. Results of a model analysis to estimate cost utility and value of information for intravenous immunoglobulin in Canadian adults with chronic immune thrombocytopenic purpura. Clin Ther 2009;31:1082-91; discussion 1066-8
21. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997; 35:1095-108
22. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002; 21:271-92
23. Brazier JE, Ratcliffe J, Tsuchiya A, et al. Measuring and valuing health for economic evaluation, Oxford: Oxford University Press, 2007